Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2022 | Long-term overall survival of AYA patients with ALL who complete therapy on DFCI Consortium trials

Marlise Luskin • 11 Dec 2022

ASH 2022

Acute Lymphoblastic Leukemia Leukemia

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) treated with Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Abbvie: Research Funding; Pfizer: Honoraria; Novartis: Research Funding.

Venetoclax & dose-reduced chemotherapy for the treatment of older adults with B-ALL and T-ALL

Marlise Luskin • 10 Dec 2023

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Marlise Luskin • 10 Dec 2023

Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial

Marlise Luskin • 10 Dec 2023

Intensity of induction regimens and outcomes of patients with Ph+ ALL undergoing alloSCT

Marlise Luskin • 11 Dec 2022

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024